Investor’s Alert: Zoetis Inc (NYSE:ZTS), Mylan Inc (NASDAQ:MYL), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Actavis plc Ordinary Shares (NYSE:ACT)

Jefferies Group reissued their buy rating on shares of Zoetis (NYSE:ZTS)in a research report sent to investors on Tuesday morning, AR Networkreports. The firm currently has a $37.00 price target on the stock, down from their previous price target of $38.00.  Zoetis Inc (NYSE:ZTS) stock opened at $31.23 in last session, and closed at $30.89, while the day range of ZTS stock is $30.80-$31.30.The stock showed a positive weekly performance of 2.52%.

Mylan (NASDAQ:MYL) was downgraded by research analysts at Needham & Company from a “buy” rating to a “hold” rating in a report released on Friday, ARN reports. Mylan Inc (NASDAQ:MYL) stock opened at $56.15, in last session and closed at $57.20, by gained 3.03%. The 52 week range was $27.66-$57.52.Company’s market capitalization is $21.89 billion.

Neurocrine Biosciences (NASDAQ:NBIX) saw some unusual options trading on Tuesday. Investors acquired 3,590 put options on the stock,Stock Ratings Network.com reports. This represents an increase of approximately 430% compared to the typical volume of 677 put options. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock gained 6.90% and finished the last session at $17.82.The EPS of the stock remained -0.69. Company’s market capitalization is $1.34 billion.

Argus raised their target price on shares of Actavis plc Ordinary Shares (NYSE:ACT) from $198.00 to $225.00 in a research note issued on Tuesday, Analyst Ratings Network reports. Argus’ price objective indicates a potential downside of 0.99% from the company’s current price.  Actavis plc Ordinary Shares (NYSE:ACT) stock opened the session at $222.52, and closed the session at $226.12.The 52 week range of the ACT stock remained $85.28-$230.77 and the day range was $22.38-$227.39.